# Sanofi: Form 20-F for the period ended Dec 31, 2021

- Company: [Sanofi](/companies/sny.md) (CIK 1121404)
- Form: 20-F
- Filed: 2022-02-23
- Accepted by EDGAR: Feb 23, 2022, 13:00 ET
- Period: 2021-12-31
- Accession: 0001121404-22-000007
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1121404/000112140422000007/sny-20211231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1121404/000112140422000007/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 12 months, 2021-01-01 to 2021-12-31 | EUR 12.26bn | ifrs-full:CostOfSales |
| Gross profit | 12 months, 2021-01-01 to 2021-12-31 | EUR 26.92bn | ifrs-full:GrossProfit |
| Operating income | 12 months, 2021-01-01 to 2021-12-31 | EUR 8.13bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2021-01-01 to 2021-12-31 | EUR 1.56bn | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2021-01-01 to 2021-12-31 | EUR 6.22bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Operating cash flow | 12 months, 2021-01-01 to 2021-12-31 | EUR 10.52bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | at 2021-12-31 | EUR 10.10bn | ifrs-full:CashAndCashEquivalents |
| Total assets | at 2021-12-31 | EUR 120.24bn | ifrs-full:Assets |
| Shareholders' equity | at 2021-12-31 | EUR 68.68bn | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | at 2021-12-31 | 1,263,560,695 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1121404/000112140422000007/sny-20211231.htm

Filed Feb 23, 2022.
Source: SEC EDGAR, the filing index for accession 0001121404-22-000007. Last ingested by Listed: Nov 5, 2026, 12:26 ET. No prices; not investment advice.